The study will evaluate the safety and efficacy of melatonin supplementation in CKD and ESRD patients with sleep disorders to reduce sleep latency times, the number of apnea/hypopneic episodes, and prolong duration in rapid eye movement (REM) sleep in CKD and ESRD patients with sleep disordered breathing.

Brief Title

Different Doses of Oral Melatonin Supplements in Chronic Kidney Disease (CKD)-Associated Sleep Disorders

Official Title

A Randomized, Prospective, Double Blind, Placebo-Controlled Trial of Two Different Doses of Oral Melatonin Supplements in Chronic Kidney Disease (CKD)-Associated Sleep Disorders

Brief Summary

The study will evaluate the safety and efficacy of melatonin supplementation in CKD and ESRD<br /> patients with sleep disorders to reduce sleep latency times, the number of apnea/hypopneic<br /> episodes, and prolong duration in rapid eye movement (REM) sleep in CKD and ESRD patients<br /> with sleep disordered breathing.

Detailed Description

The study will look at the safety and efficacy of melatonin supplementation given to patients
with chronic kidney disease and end stage renal disease who have sleep disorders to reduce
sleep latency times, the number of apnea/hypopneic episodes, and prolong duration in rapid
eye movement (REM) sleep in CKD and ESRD patients with sleep disordered breathing.

Outcome Measures

Outcome measures are the tests that investigators perform to prove whether or not a treatment being tested in a clinical trial is having any effect.